Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung...

41
Indicazioni alla terapia adiuvante Vito Lorusso Dipartimento di Oncologia Medica Istituto Oncologico Bari

Transcript of Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung...

Page 1: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient

Indicazioni alla terapiaadiuvante

Vito LorussoDipartimento di Oncologia Medica

Istituto Oncologico Bari

Page 2: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 3: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 4: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 5: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 6: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 7: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 8: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 9: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 10: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 11: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 12: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 13: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 14: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 15: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 16: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 17: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 18: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 19: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 20: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 21: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 22: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 23: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 24: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 25: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 26: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 27: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 28: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 29: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 30: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 31: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 32: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 33: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 34: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 35: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 36: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 37: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 38: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 39: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 40: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient
Page 41: Indicazioni alla terapia adiuvante...IALT Advances m Management of Early Stage Non Small Cell Lung Cancer -Accrual 1867 / 3300 - Median Survival 50.8 months vs 44.4 months .Patient

Radioterapia*ipofrazionata*ad*intensità*modulata* con ... · Radioterapia*ipofrazionata*ad*intensità*modulata* con*boost**simultaneo*integrato*per*l’irradiazione** adiuvante*della*mammella*u8lizzando*campi*

Radioterapia*ipofrazionata*ad*intensità*modulata* con ... · Radioterapia*ipofrazionata*ad*intensità*modulata* con*boost**simultaneo*integrato*per*l’irradiazione** adiuvante*della*mammella*u8lizzando*campi*

The Swedish guarantee program · 1 week 2 weeks 4 weeks 2 months 3 months 4 months 5 months 6 months 7 months 8 months 9 months 10 months 11 months 12 months. SEB is match-funded

The Swedish guarantee program · 1 week 2 weeks 4 weeks 2 months 3 months 4 months 5 months 6 months 7 months 8 months 9 months 10 months 11 months 12 months. SEB is match-funded

Glow Blogs – Just another blogs.glowscotland.org.uk weblog · Web viewLiteracy. IALT decode words using phonemes. Phonics Task- consolidation . Starter- Alphabet name and sounds-

Glow Blogs – Just another blogs.glowscotland.org.uk weblog · Web viewLiteracy. IALT decode words using phonemes. Phonics Task- consolidation . Starter- Alphabet name and sounds-

MONTHS MONTHS - Preen

MONTHS MONTHS - Preen

Terapia neo-adiuvante MALATTIA TRIPLO NEGATIVA...Linee guida AIOM 2018; Early Breast Cancer: St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer

Terapia neo-adiuvante MALATTIA TRIPLO NEGATIVA...Linee guida AIOM 2018; Early Breast Cancer: St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer

files.schudio.com€¦ · Web viewWeek 5 WB 29th June 2020 Monday Maths IALT multiply by 5 Starter: Daily 10 Main: Follow the link for videos, practice questions and quizzes. ...

files.schudio.com€¦ · Web viewWeek 5 WB 29th June 2020 Monday Maths IALT multiply by 5 Starter: Daily 10 Main: Follow the link for videos, practice questions and quizzes. ...

Terapia Neo-adiuvante: malattia triplo negativa Valentina ...media.aiom.it/userfiles/files/doc/AIOM-Servizi/... · N=1,320 •Study to start recruiting patients with TNBC; plan to

Terapia Neo-adiuvante: malattia triplo negativa Valentina ...media.aiom.it/userfiles/files/doc/AIOM-Servizi/... · N=1,320 •Study to start recruiting patients with TNBC; plan to

May 12th 2017, 13.30-15.00 Amber Hall 5-6 · L’adsorbimento di citochine come terapia adiuvante nello shock settico - S. Mitzner (Rostock) L’adsorbimento di citochine come terapia

May 12th 2017, 13.30-15.00 Amber Hall 5-6 · L’adsorbimento di citochine come terapia adiuvante nello shock settico - S. Mitzner (Rostock) L’adsorbimento di citochine come terapia

LA!RADIOTERAPIA!ADIUVANTE!! … · LA!RADIOTERAPIA!ADIUVANTE!! NEL!TRATTAMENTO!DEI!CARCINOMI!! AD!ALTO!RISCHIO!DELLA!TIROIDE:!CONS! ROMA! Associazione!Italiana!Radioterapia!Oncologica!

LA!RADIOTERAPIA!ADIUVANTE!! … · LA!RADIOTERAPIA!ADIUVANTE!! NEL!TRATTAMENTO!DEI!CARCINOMI!! AD!ALTO!RISCHIO!DELLA!TIROIDE:!CONS! ROMA! Associazione!Italiana!Radioterapia!Oncologica!

blogs.glowscotland.org.uk€¦  · Web view2020-05-18 · Literacy. IALT decode words using phonemes. News- All about today. We are going to begin with our ‘all about today’

blogs.glowscotland.org.uk€¦  · Web view2020-05-18 · Literacy. IALT decode words using phonemes. News- All about today. We are going to begin with our ‘all about today’

Raccomandazioni per il trattamento adiuvante del ... · Van Gool – Belgium Switzerland, Spain, Netherlands, Scandinavia, Others? Biology group: Declared representatives so far.

Raccomandazioni per il trattamento adiuvante del ... · Van Gool – Belgium Switzerland, Spain, Netherlands, Scandinavia, Others? Biology group: Declared representatives so far.

Terapia adiuvante con inibitori delle Kinasi Cliclina …media.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6:

Terapia adiuvante con inibitori delle Kinasi Cliclina …media.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6:

Ialt( /IIAF 10 Oct VI01 OPT.pdf · Ialt(/IIAF&?H INFANTRY DIVISION ASSOCIAIION vol. w ooToBER 19t2 NO.I Paet secretar"rGi-EdIfor-oi- the Taro Iraf,Bob fruff (Div Hq) was elected to

Ialt( /IIAF 10 Oct VI01 OPT.pdf · Ialt(/IIAF&?H INFANTRY DIVISION ASSOCIAIION vol. w ooToBER 19t2 NO.I Paet secretar"rGi-EdIfor-oi- the Taro Iraf,Bob fruff (Div Hq) was elected to

Translatio 2017, Nr 1 · BDUE, ADUE Nord and IALT Institut für Angewandte Linguistik und Translatologie (Associate Member of FIT) in Leipzig. Also noteworthy are the activities hosted

Translatio 2017, Nr 1 · BDUE, ADUE Nord and IALT Institut für Angewandte Linguistik und Translatologie (Associate Member of FIT) in Leipzig. Also noteworthy are the activities hosted

Carcinoma della Mammella Novità in tema di …media.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...Carcinoma della Mammella Novità in tema di Adiuvante Antonella Palazzo, MD,

Carcinoma della Mammella Novità in tema di …media.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/...Carcinoma della Mammella Novità in tema di Adiuvante Antonella Palazzo, MD,

St Bede’s Newsletter-Transition Issue 2 · 2020-06-26 · St Bede‟s Catholic Comprehensive School & Byron Sixth Form College „Domino Adiuvante‟ 26/06/2020 Westway, Peterlee,

St Bede’s Newsletter-Transition Issue 2 · 2020-06-26 · St Bede‟s Catholic Comprehensive School & Byron Sixth Form College „Domino Adiuvante‟ 26/06/2020 Westway, Peterlee,

Percorsi diagnostico-terapeutici integrati: IN ADIUVANTE L. Del Mastro, G. Tuccari

Percorsi diagnostico-terapeutici integrati: IN ADIUVANTE L. Del Mastro, G. Tuccari

Supply chain infographic-2-FINAL - IFPMA...SUPPLY CHAIN POST-APPROVAL CHANGE: 0 6 months 12 months 18 months 24 months 30 months 36 months 42 months 48 months Global Complexity Contributing

Supply chain infographic-2-FINAL - IFPMA...SUPPLY CHAIN POST-APPROVAL CHANGE: 0 6 months 12 months 18 months 24 months 30 months 36 months 42 months 48 months Global Complexity Contributing

Utah Immunization Guidebookhealth.utah.gov/licensing/IPiCC/docs/Immunization_Guidebook.pdfRecommended Immunization Schedule Birth 2 months 4 months 6 months 12 months 15 months 18

Utah Immunization Guidebookhealth.utah.gov/licensing/IPiCC/docs/Immunization_Guidebook.pdfRecommended Immunization Schedule Birth 2 months 4 months 6 months 12 months 15 months 18

Early Motor Development...9.5 months 9 months 10 months Denver II Walks alone/ Rise to stand without support 13.1 months 15 months 18 months (or if regression) 14.4 months WHO Motor

Early Motor Development...9.5 months 9 months 10 months Denver II Walks alone/ Rise to stand without support 13.1 months 15 months 18 months (or if regression) 14.4 months WHO Motor